Caribou Biosciences Announces the FDA Granted Regenerative Medicine Advanced Therapy (RMAT) Designation to CB-011, an Allogeneic Anti-BCMA CAR-T Cell Therapy

RMAT granted based on promising initial clinical data, including previously disclosed recommended dose for expansion data of 92% ORR, 75% ≥CR ...
Targeted Oncology

FDA Grants RMAT Designation to Allogeneic CAR T for R/R Multiple Myeloma

CB-011, an allogeneic CAR T product, received RMAT designation as treatment for multiple myeloma based on strong dose ...

Caribou rises on FDA RMAT designation for CAR-T therapy

Caribou Biosciences (CRBU) added ~9% in the premarket on Tuesday after the company announced that the U.S. FDA issued the Regenerative Medicine Advanced Therapy (RMAT) designation for its CAR-T cell ...
Nasdaq

Caribou Biosciences Initiates Phase 1 Clinical Trials for CB-010 in Lupus and Advances Multiple CAR-T Therapy Programs

Caribou Biosciences announces new clinical trials and leadership appointments, highlighting progress in CAR-T therapy for various cancers and lupus. Caribou Biosciences, Inc. announced the initiation ...